Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) EBIT: 2009-2025

Historic EBIT for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to -$1.5 million.

  • Aytu Biopharma's EBIT fell 61.72% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 274.71%. This contributed to the annual value of -$7.8 million for FY2025, which is 259.20% down from last year.
  • Latest data reveals that Aytu Biopharma reported EBIT of -$1.5 million as of Q3 2025, which was up 80.27% from -$7.6 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's EBIT registered a high of $3.1 million during Q4 2023, and its lowest value of -$53.4 million during Q1 2022.
  • For the 3-year period, Aytu Biopharma's EBIT averaged around -$1.8 million, with its median value being -$1.5 million (2025).
  • Its EBIT has fluctuated over the past 5 years, first slumped by 1,792.90% in 2024, then surged by 251.60% in 2025.
  • Over the past 5 years, Aytu Biopharma's EBIT (Quarterly) stood at -$11.3 million in 2021, then surged by 39.19% to -$6.9 million in 2022, then surged by 145.81% to $3.1 million in 2023, then tumbled by 153.88% to -$1.7 million in 2024, then slumped by 61.72% to -$1.5 million in 2025.
  • Its EBIT stands at -$1.5 million for Q3 2025, versus -$7.6 million for Q2 2025 and $2.4 million for Q1 2025.